BRAINSTORM CELL THERAPEUTICS INC. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent of -$2.11 million for the 3-month period ending 2014-03-31, per its 10-Q filed 2014-05-13.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromContinuingOperations · last filed 2014-05-13
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2014-03-31 was -$2.11M.
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2013-12-31 was -$1.22M.
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2013-09-30 was -$1.08M.
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2013-06-30 was -$1.52M.
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2013 was -$4.90M.
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2012 was -$3.43M.
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2011 was -$3.92M, a 261.97% decline from fiscal 2010.
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2010 was $2.42M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 3 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 6 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 6 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 9 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 9 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 12 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 12 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 129 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 132 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 135 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 138 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 141 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 144 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 147 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 150 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 153 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 156 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 159 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 162 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | -$2.11M 10-Q · filed 2014-05-13 | -$3.33M derived: sum of 2 quarters · filed 2014-05-13 | -$4.41M derived: sum of 3 quarters · filed 2014-05-13 | -$5.93M derived: sum of 4 quarters · filed 2014-05-13 | -$54.35M 10-Q · filed 2014-05-13 | |||||||||||||||
| 2013-12-31 | -$1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | -$2.30M derived: sum of 2 quarters · filed 2014-03-27 | -$3.82M derived: sum of 3 quarters · filed 2014-03-27 | -$4.90M 10-K · filed 2014-03-27 | -$52.24M 10-K · filed 2014-03-27 | |||||||||||||||
| 2013-09-30 | -$1.08M 10-Q · filed 2013-11-14 | -$2.60M derived: sum of 2 quarters · filed 2013-11-14 | -$3.68M 10-Q · filed 2013-11-14 | -$4.26M derived: sum of 4 quarters · filed 2014-05-13 | -$51.03M 10-Q · filed 2013-11-14 | |||||||||||||||
| 2013-06-30 | -$1.52M 10-Q · filed 2013-08-14 | -$2.60M 10-Q · filed 2013-08-14 | -$3.18M derived: sum of 3 quarters · filed 2014-05-13 | -$4.33M derived: sum of 4 quarters · filed 2014-05-13 | -$49.94M 10-Q · filed 2013-08-14 | |||||||||||||||
| 2013-03-31 | -$1.08M 10-Q · filed 2014-05-13 | -$1.66M derived: sum of 2 quarters · filed 2014-05-13 | -$2.81M derived: sum of 3 quarters · filed 2014-05-13 | -$3.64M derived: sum of 4 quarters · filed 2014-05-13 | -$48.43M 10-Q · filed 2013-05-09 | |||||||||||||||
| 2012-12-31 | -$579.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | -$1.73M derived: sum of 2 quarters · filed 2014-03-27 | -$2.56M derived: sum of 3 quarters · filed 2014-03-27 | -$3.43M 10-K · filed 2014-03-27 | -$47.34M 10-K · filed 2013-03-14 | |||||||||||||||
| 2012-09-30 | -$1.15M 10-Q · filed 2013-11-14 | -$1.98M derived: sum of 2 quarters · filed 2013-11-14 | -$2.85M 10-Q · filed 2013-11-14 | -$4.27M derived: sum of 4 quarters · filed 2013-11-14 | -$46.77M 10-Q · filed 2012-11-13 | |||||||||||||||
| 2012-06-30 | -$830.00K 10-Q · filed 2013-08-14 | $830.00K 10-Q/A · filed 2012-08-29 | -$1.70M 10-Q · filed 2013-08-14 | $1.70M 10-Q/A · filed 2012-08-29 | -$3.12M derived: sum of 3 quarters · filed 2013-08-14 | -$3.82M derived: sum of 4 quarters · filed 2013-08-14 | $45.62M 10-Q/A · filed 2012-08-29 | |||||||||||||
| 2012-03-31 | -$872.00K 10-Q · filed 2013-05-09 | $872.00K 10-Q · filed 2012-05-11 | -$2.29M derived: sum of 2 quarters · filed 2013-05-09 | -$2.99M derived: sum of 3 quarters · filed 2013-05-09 | -$1.89M derived: sum of 4 quarters · filed 2013-05-09 | $44.79M 10-Q · filed 2012-05-11 | ||||||||||||||
| 2011-12-31 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-14 | -$2.12M derived: sum of 2 quarters · filed 2013-03-14 | -$1.02M derived: sum of 3 quarters · filed 2013-03-14 | -$3.92M 10-K · filed 2013-03-14 | $3.92M 10-K · filed 2012-03-15 | $43.91M 10-K · filed 2012-03-15 | ||||||||||||||
| 2011-09-30 | -$694.00K 10-Q · filed 2012-11-13 | $694.00K 10-Q · filed 2011-11-14 | $403.00K derived: sum of 2 quarters · filed 2012-11-13 | -$2.50M 10-Q · filed 2012-11-13 | $2.50M 10-Q · filed 2011-11-14 | $1.59M derived: sum of 4 quarters · filed 2012-11-13 | $42.49M 10-Q · filed 2011-11-14 | |||||||||||||
| 2011-06-30 | $1.10M 10-Q/A · filed 2012-08-29 | $1.80M 10-Q/A · filed 2012-08-29 | $2.29M derived: sum of 3 quarters · filed 2012-08-29 | $2.99M derived: sum of 4 quarters · filed 2012-08-29 | $41.80M 10-Q/A · filed 2011-09-07 | |||||||||||||||
| 2011-03-31 | $705.00K 10-Q · filed 2012-05-11 | $1.19M derived: sum of 2 quarters · filed 2012-05-11 | $1.90M derived: sum of 3 quarters · filed 2012-05-11 | $2.51M derived: sum of 4 quarters · filed 2012-05-11 | ||||||||||||||||
| 2010-12-31 | $486.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-15 | $1.19M derived: sum of 2 quarters · filed 2012-03-15 | $1.80M derived: sum of 3 quarters · filed 2012-03-15 | $2.42M 10-K · filed 2012-03-15 | ||||||||||||||||
| 2010-09-30 | $704.00K 10-Q · filed 2011-11-14 | $1.32M derived: sum of 2 quarters · filed 2011-11-14 | $1.93M 10-Q · filed 2011-11-14 | |||||||||||||||||
| 2010-06-30 | $614.00K 10-Q/A · filed 2011-09-07 | $1.23M 10-Q/A · filed 2011-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |